



## PRESS RELEASE

**EMBARGOED UNTIL 8:00AM PDT  
April 25, 2005**

## FOR MORE INFORMATION:

### Contacts:

Jonathan Mow  
Corus Pharma  
206-792-3020

[jmow@coruspharma.com](mailto:jmow@coruspharma.com)

Leslie Cohan  
Dave Syferd & Partners  
206-262-0395 (office)  
206-849-1810 (cell)

[lcohan@dsandp.com](mailto:lcohan@dsandp.com)

## **PHASE 3 CLINICAL TRIAL INITIATED FOR CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS**

Corus Pharma Announces Phase 3 Trial for Aztreonam Lysinate for Inhalation

**SEATTLE** – Corus Pharma has begun enrolling patients in its AIR-CF2 Phase 3 clinical trial for Aztreonam Lysinate for Inhalation (*CAYSTON™* or AI). The multi-center, blinded, placebo controlled trial will be conducted in 50 cystic fibrosis (CF) centers in the United States, and will evaluate the efficacy and safety of AI in CF patients with pulmonary *Pseudomonas aeruginosa*. More detailed information on AI and the trial can be found at [www.air-cf.com](http://www.air-cf.com) or [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

Aztreonam is an antibiotic that has activity against a broad spectrum of Gram-negative bacteria, including *Pseudomonas aeruginosa*, which commonly infect the lungs of CF patients. AI is a reconstituted solution which is specifically formulated for inhalation. Inhaled delivery concentrates the drug in the lungs, the predominant site of infection in CF patients. AI is delivered by the eFlow<sup>®</sup> Electronic Nebulizer developed by PARI GmbH with an average treatment time in Corus' Phase 2 clinical trial of less than three minutes.

“This is a significant milestone for the development of a potential treatment for cystic fibrosis patients and for our organization,” comments A. Bruce Montgomery, MD, CEO Corus Pharma. “We look forward to the results of this study so that we can submit Phase 3 clinical data to regulatory authorities.”

###

### **About Cystic Fibrosis**

Cystic Fibrosis is a genetic disease that affects approximately 30,000 children and adults in the United States and a similar number in Europe. A major characteristic of CF is production of abnormally-thick, sticky mucus in the lungs, which traps bacteria and predisposes patients to infection, thereby continually damaging their lungs.

### **About Corus Pharma**

Corus Pharma is committed to developing and commercializing products for severe respiratory and infectious diseases that can help provide improved health and quality of life. More information about Corus Pharma may be found at [www.coruspharma.com](http://www.coruspharma.com). For more information about the AI Phase 3 clinical trials, go to [www.air-cf.com](http://www.air-cf.com) or [www.clinicaltrials.gov](http://www.clinicaltrials.gov).